GlobeNews Wire

DRML Miner Launches Innovative USDC Cloud Mining Platform: Experience Daily Rewards and Referral Bonuses at Zero Cost

New York, NY, July 01, 2025 (GLOBE NEWSWIRE) -- A Trusted Gateway to Risk-Free Crypto Earnings As financial uncertainty increases,…

10 months ago

Processa Pharmaceuticals Provides Portfolio and Business Update

Signed binding term sheet granting Intact Therapeutics an exclusive option to license PCS12852Continue enrolling patients in Phase 2 study of…

10 months ago

Inmagene Doses First Patient in the ADAPTIVE Phase 2b Trial of IMG-007, a Nondepleting Anti-OX40 mAb with an Extended Half-life, in Patients with Moderate-to-Severe Atopic Dermatitis

July 01, 2025 09:00 ET  | Source: Inmagene Biopharmaceuticals The ADAPTIVE Phase 2b trial evaluates multiple dose regimens of IMG-007…

10 months ago

Visory Health Wins Gold at the 2025 Digital Health Awards

ESTERO, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Visory Health, a leading patient-first health tech prescription platform that is transforming…

10 months ago

Acceleware Announces Non-Brokered Private Placement of Units and Shares for Debt Transactions

CALGARY, Alberta, June 30, 2025 (GLOBE NEWSWIRE) -- Acceleware® Ltd. (“Acceleware” or the “Company”) (TSX-V: AXE), a leading innovator of…

10 months ago

Acesis Biomed Secures Patents Advancing Testosterone-Inducing Drug Development

Centennial, Colorado, June 30, 2025 (GLOBE NEWSWIRE) -- Acesis Holdings Corporation (“Acesis Biomed”), a pre-clinical stage biomedical company pioneering oral treatments…

10 months ago

Shoals Technologies Group, Inc. Announces Battery Energy Storage Systems (BESS) Webinar

PORTLAND, Tenn., June 30, 2025 (GLOBE NEWSWIRE) -- Shoals Technologies Group, Inc. (“Shoals” or the “Company”) (Nasdaq: SHLS), a global…

10 months ago

Transactions under Novonesis share buyback program

Novonesis has now completed the announced share buyback program of B shares worth up to EUR 100 million (DKK 746…

10 months ago

OSE Immunotherapeutics Publishes Letter to Shareholders

OSE Immunotherapeutics Publishes Letter to Shareholders NANTES, France, June 30, 2025, 6:00 p.m. - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo:…

10 months ago

IBA Transparency Notification – Denominator

June 30, 2025 12:00 ET  | Source: IBA SA                                                                                                                   June 30th, 2025 Publication made under article 15 of the…

10 months ago